RxDoctor Payments Data

Robert Feldman, MD

Internal Medicine · Rockledge, PANPI 1184620627

Payments from drug & device makers

$552in general payments, 2019–2025

Across 33 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$118
  • Pfizer$105
  • Johnson & Johnson$72
  • AbbVie$56
  • Novo Nordisk$42
  • GSK$40
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$552 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$192,011
Medicare patients
434
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin114$133,110
EliquisApixaban92$94,510
JanuviaSitagliptin Phosphate74$83,974
OzempicSemaglutide43$54,381
Repatha SureclickEvolocumab62$47,738
XareltoRivaroxaban42$45,786
MounjaroTirzepatide34$44,268
TrulicityDulaglutide20$30,969
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$28,592
Tresiba Flextouch U-100Insulin Degludec51$26,649
FarxigaDapagliflozin Propanediol26$25,343
Bydureon BciseExenatide Microspheres14$14,179
VascepaIcosapent Ethyl22$12,913
Breo ElliptaFluticasone/Vilanterol21$11,967
Pantoprazole Sodium246$6,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$105$94,51092 claims
MerckJanuvia$12$83,97474 claims
Lilly USA, LLCMounjaro, Trulicity$23$75,23754 claims
Novo NordiskOzempic$42$54,38143 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$40$47,43263 claims
Johnson & JohnsonXarelto$72$45,78642 claims
AstraZenecaFarxiga$14$25,34326 claims
AbbVieSynthroid$56$2,97431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Rockledge

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →